PharmaCyte Biotech
PMCB
PMCB
29 hedge funds and large institutions have $3.47M invested in PharmaCyte Biotech in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 13 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
less ownership
Funds ownership: →
66% less capital invested
Capital invested by funds: $10.2M → $3.47M (-$6.75M)
77% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 13
93% less call options, than puts
Call options by funds: $27K | Put options by funds: $366K
Holders
29
Holding in Top 10
1
Calls
$27K
Puts
$366K
Top Buyers
| 1 | +$125K | |
| 2 | +$74K | |
| 3 | +$47.5K | |
| 4 |
CL
CSS LLC
Chicago,
Illinois
|
+$37.7K |
| 5 |
Carson Wealth (CWM LLC)
Omaha,
Nebraska
|
+$3K |
Top Sellers
| 1 | -$2.16M | |
| 2 | -$1.63M | |
| 3 | -$1.48M | |
| 4 |
EPM
Equitec Proprietary Markets
Chicago,
Illinois
|
-$770K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$311K |